EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Enterprise Value : $0.00 Mil (As of May. 30, 2024)

EPIRUS Biopharmaceuticals Enterprise Value Chart

EPIRUS Biopharmaceuticals Annual Data
	Trend	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15
Enterprise Value		Get a 7-Day Free Trial					92.78	64.23	63.01	59.07	58.64

EPIRUS Biopharmaceuticals Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Enterprise Value	Get a 7-Day Free Trial															156.21	90.80	78.18	58.64	64.42

Competitive Comparison of EPIRUS Biopharmaceuticals's Enterprise Value

For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EPIRUS Biopharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where EPIRUS Biopharmaceuticals's Enterprise Value falls into.

EPIRUS Biopharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EPIRUS Biopharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as

EPIRUS Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EPIRUS Biopharmaceuticals  (OTCPK:EPRSQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

EPIRUS Biopharmaceuticals's EV-to-EBIT for today is

EPIRUS Biopharmaceuticals's current Enterprise Value is $0.00 Mil.
EPIRUS Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-61.09 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

EPIRUS Biopharmaceuticals's EV-to-EBITDA for today is:

EPIRUS Biopharmaceuticals's current Enterprise Value is $0.00 Mil.
EPIRUS Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.30 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

EPIRUS Biopharmaceuticals's EV-to-Revenue for today is:

EPIRUS Biopharmaceuticals's current Enterprise Value is $0.00 Mil.
EPIRUS Biopharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EPIRUS Biopharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description